

Ching-Lung Lai

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5232674/ching-lung-lai-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

370
papers

29,739
citations

85
h-index

162
g-index

380
ext. papers

33,239
ext. citations

7.8
avg. IF

6.77
L-index

#	Paper	IF	Citations
370	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2021 ,	19.2	7
369	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	47
368	Serum ceruloplasmin monitoring in a case of silver intoxication due to intravenous silver infusion. <i>Clinical Toxicology</i> , 2021 , 1-4	2.9	0
367	Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials. <i>Clinical Endocrinology</i> , 2021 , 95, 478-488	3.4	4
366	Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. <i>Biomedicines</i> , 2021 , 9,	4.8	25
365	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. <i>Vaccines</i> , 2021 , 9,	5.3	7
364	Rebound of HBV DNA after cessation of nucleos(tide) analogues in chronic hepatitis B patients with undetectable covalently closed. <i>JHEP Reports</i> , 2020 , 2, 100112	10.3	9
363	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , 2020 , 5, 1129-1138	4.1	6
362	HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. <i>Scientific Reports</i> , 2020 , 10, 802	4.9	9
361	RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020 , 72, 19-31	11.2	47
360	Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B. <i>Hepatology</i> , 2020 , 72, 818-828	11.2	5
359	A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 397-406	3.4	8
358	Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 449-456	6.9	28
357	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1924-1933	7	17
356	Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. <i>Hepatology International</i> , 2019 , 13, 148-156	8.8	8
355	Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1229-1232	3.4	2
354	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2019 , 220, 940-950	7	2

353	Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 818-827	3.4	19
352	Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1473-1480	3.4	7
351	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 3630-3641	4	
350	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2019 , 25, 1398-1408	5.6	9
349	Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1817-1823	4	9
348	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2019 , 171, 496-504	8	11
347	Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1410-1412	6.9	7
346	Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 101-106	5.5	2
345	An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 483-491	5.5	4
344	Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. <i>Hepatology</i> , 2018 , 68, 462-472	11.2	39
343	Association Between Hepatic Steatosis, Measured by Controlled \square Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 575-583.e2	6.9	46
342	Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 43-54	6.1	105
341	Hepatitis B virus infection. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 18035	51.1	250
340	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018 , 38, 1179-1187	7.9	16
339	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , 2018 , 94, 663-673	9.9	54
338	Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. <i>Clinical and Translational Gastroenterology</i> , 2018 , 9, 163	4.2	18
337	Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 501-509	6.1	22
336	The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection. <i>Liver International</i> , 2017 , 37, 1287-1294	7.9	4

335	Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 654-661	3.4	44
334	Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. <i>Antiviral Research</i> , 2017 , 144, 1-7	10.8	28
333	Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2017 , 52, 1064-1074	6.9	9
332	Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. <i>Hepatology</i> , 2017 , 66, 1036-1044	11.2	70
331	Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. <i>Hepatology</i> , 2017 , 65, 1451-1461	11.2	60
330	Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. <i>Liver International</i> , 2017 , 37, 995-1001	7.9	91
329	Hepatitis B core protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 1153-1159	15.9	23
328	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	216
327	Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e116	4.2	35
326	Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. <i>Transplantation</i> , 2017 , 101, 2391-2398	1.8	3
325	Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e125	4.2	64
324	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e100	4.2	20
323	Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. <i>Cancer Letters</i> , 2017 , 403, 330-338	9.9	28
322	Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2017 , 6, 350-362	2.3	58
321	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1230-1233	4	14
320	Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2017 , 66, 275-281	13.4	97
319	Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. <i>Oncotarget</i> , 2017 , 8, 47507-47517	7.3	23
318	Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7716-7726	5.6	21

317	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7863-7874	5.6	7
316	Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. <i>Journal of Gastroenterology</i> , 2016 , 51, 487-95	6.9	20
315	Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1788-1795	0.7	51
314	Hepatitis B: treatment choice and monitoring for response and resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 697-707	4.2	10
313	DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 383-92	4.1	18
312	Prevention and management of hepatitis B virus reactivation in cancer patients. <i>Hepatology International</i> , 2016 , 10, 407-14	8.8	16
311	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 96-101	6.1	22
310	Emerging drugs for the treatment of hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 183-93	3.7	8
309	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016 , 10, 1-98	8.8	1288
308	Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. <i>Gut and Liver</i> , 2016 , 10, 332-9	4.8	307
307	Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016 , 11, e0148493	3.7	17
306	Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. <i>Liver International</i> , 2016 , 36, 642-50	7.9	5
305	Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 286-94	3	36
304	Hepatitis B virus full-length genomic mutations and quasispecies in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1638-45	4	8
303	Interleukin-1 β increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. <i>Oncology Letters</i> , 2016 , 11, 2919-2924	2.6	15
302	Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 1071-1079	6.1	19
301	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015 , 64, 667-72	19.2	148
300	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015 , 121, 97-108	10.8	105

299	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. <i>Antiviral Research</i> , 2015 , 121, 47-58	10.8	175
298	Management of chronic hepatitis B in patients from special populations. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015 , 5,	5.4	2
297	Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study. <i>Liver International</i> , 2015 , 35, 854-9	7.9	5
296	Hepatitis B in 2014: HBV research moves forward--receptors and reactivation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 70-2	24.2	9
295	Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. <i>Liver Transplantation</i> , 2015 , 21, 1504-10	4.5	18
294	Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. <i>Oncotarget</i> , 2015 , 6, 34941-52	3.3	38
293	Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015 , 10, e0139478	3.7	8
292	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015 , 373, 2599-607	59.2	758
291	High prevalence of non-alcoholic fatty liver disease in the Chinese - results from the Hong Kong liver health census. <i>Liver International</i> , 2015 , 35, 542-9	7.9	59
290	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. <i>Journal of Hepatology</i> , 2015 , 62, 526-32	13.4	38
289	Measuring and Validating a General Cancer Predisposition Perception Scale: An Adaptation of the Revised-IPQ-Genetic Predisposition Scale. <i>PLoS ONE</i> , 2015 , 10, e0142620	3.7	3
288	Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1764-70	0.7	15
287	Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014 , 20, 1173-80	9.5	77
286	Hepatitis Viruses and Hepatocellular Carcinoma 2014 , 181-192		2
285	Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 3209-15	9.7	9
284	Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1028-34	4	41
283	Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. <i>Journal of Infectious Diseases</i> , 2014 , 210, 701-7	7	9
282	Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. <i>PLoS ONE</i> , 2014 , 9, e99028	3.7	11

281	Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3736-43	2.2	223
280	Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 428-34	4	67
279	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. <i>Gut</i> , 2014 , 63, 996-1004	19.2	55
278	Telbivudine improves renal function in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2014 , 146, 138-146.e5	13.3	90
277	HLA-DP and Interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 533-9	4	4
276	Artificial neural network accurately predicts hepatitis B surface antigen seroclearance. <i>PLoS ONE</i> , 2014 , 9, e99422	3.7	7
275	Management of chronic hepatitis B in severe liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 16053-61	5.6	12
274	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , 2013 , 7, 327-34	8.8	2
273	Characterization of interleukin-1 β in Helicobacter pylori-induced gastric inflammation and DNA methylation in interleukin-1 receptor type 1 knockout (IL-1R1(-/-)) mice. <i>European Journal of Cancer</i> , 2013 , 49, 2760-70	7.5	34
272	Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 470-7	3.4	22
271	Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. <i>Hepatology</i> , 2013 , 58, 923-31	11.2	70
270	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. <i>Hepatology</i> , 2013 , 57, 399-408	11.2	157
269	Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1004-10.e1	6.9	98
268	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. <i>Journal of Hepatology</i> , 2013 , 59, 709-16	13.4	43
267	Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. <i>American Journal of Gastroenterology</i> , 2013 , 108, 942-8	0.7	94
266	Reply to Liao et al. <i>Clinical Infectious Diseases</i> , 2013 , 57, 622	11.6	1
265	Use of liver stiffness measurement for liver resection surgery: correlation with indocyanine green clearance testing and post-operative outcome. <i>PLoS ONE</i> , 2013 , 8, e72306	3.7	26
264	HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1695-703	11.6	52

263	Factors for hepatitis B vaccination and abnormal liver function in Chinese patients with inflammatory bowel disease: a single center experience. <i>Journal of Digestive Diseases</i> , 2013 , 14, 596-603 ^{3:3}	4
262	Reply: To PMID 22806323. <i>Hepatology</i> , 2013 , 58, 1857	11.2 1
261	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir. <i>Antiviral Therapy</i> , 2013 , 18, 691-8	1.6 15
260	Defining normal liver stiffness range in a normal healthy Chinese population without liver disease. <i>PLoS ONE</i> , 2013 , 8, e85067	3.7 29
259	Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. <i>PLoS ONE</i> , 2013 , 8, e66920	3.7 31
258	Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013 , 2, 34-6	2.1
257	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8887-94	5.6 33
256	Acute-on-chronic liver failure in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 662-9	4 51
255	Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. <i>Hepatology International</i> , 2012 , 7, 98-105	8.8 24
254	Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. <i>Hepatology International</i> , 2012 , 7, 119-26	8.8 9
253	High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 1047-1050.e1 ^{6:9}	12
252	A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. <i>PLoS ONE</i> , 2012 , 7, e32622	3.7 53
251	High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. <i>PLoS ONE</i> , 2012 , 7, e43087	3.7 59
250	A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. <i>Hepatology</i> , 2012 , 56, 812-9	11.2 68
249	Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. <i>Antiviral Therapy</i> , 2012 , 17, 1255-62	1.6 15
248	Future prevention and treatment of chronic hepatitis B infection. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 725-34	3 4
247	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy. <i>Journal of Hepatology</i> , 2011 , 54, 195-200	13.4 24
246	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , 2011 , 55, 522-528	13.4 30

245	Ketamine-induced cholangiopathy: a case report. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1004-5	7	22
244	A comprehensive HBV array for the detection of HBV mutants and genotype. <i>Clinical Biochemistry</i> , 2011 , 44, 1253-60	3.5	5
243	Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. <i>PLoS ONE</i> , 2011 , 6, e28798	3.7	53
242	Treatment of chronic hepatitis B: Evolution over two decades. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26 Suppl 1, 138-43	4	130
241	To stop or not to stop: the quest for long-term viral suppression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 420-2	4	2
240	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 738-44	3.4	38
239	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e200-5	3.4	44
238	Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. <i>Liver International</i> , 2011 , 31, 1494-504	7.9	95
237	The use of transient elastography in the management of chronic hepatitis B. <i>Hepatology International</i> , 2011 , 5, 868-875	8.8	13
236	Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. <i>Current Hepatitis Reports</i> , 2011 , 10, 106-111		8
235	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011 , 10, 235-243		21
234	Stability of hepatitis B surface antigen over time: implications for studies using stored sera. <i>Journal of Medical Virology</i> , 2011 , 83, 1900-4	19.7	7
233	Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years. <i>Hepatology</i> , 2011 , 53, 1148-53	11.2	11
232	Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. <i>Hepatology</i> , 2011 , 54, 829-36	11.2	106
231	Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. <i>Clinical Infectious Diseases</i> , 2011 , 52, 624-32	11.6	68
230	Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. <i>Gastroenterology</i> , 2011 , 141, 1212-9	13.3	169
229	Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1264-7	19.7	117
228	Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1766-73	0.7	51

227	Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B. <i>American Journal of Gastroenterology</i> , 2011 , 106, 492-6	0.7	46
226	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2715-25	5.1	139
225	Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. <i>Journal of Infectious Diseases</i> , 2011 , 203, 646-54	7	76
224	The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1007-8	0.7	14
223	A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. <i>PLoS ONE</i> , 2011 , 6, e23077	3.7	61
222	Systemic corticosteroid and reactivation of chronic hepatitis B. <i>Respirology</i> , 2010 , 15, 1017-8	3.6	9
221	Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 882-9	5.9	29
220	Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. <i>Gut</i> , 2010 , 59, 1389-93	19.2	47
219	Safety evaluation of telbivudine. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 821-9	4.1	22
218	Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1116-22	0.7	44
217	Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2010 , 8, 717-26	5.5	15
216	Natural history of chronic hepatitis C: genotype 1 versus genotype 6. <i>Journal of Hepatology</i> , 2010 , 53, 444-8	13.4	33
215	Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. <i>Hepatology International</i> , 2010 , 4, 716-22	8.8	26
214	Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010 , 51, 422-30	11.2	433
213	Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. <i>Hepatology</i> , 2010 , 51, 1185-9	11.2	35
212	Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. <i>Hepatology</i> , 2010 , 51, 767-76	11.2	36
211	Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. <i>Hepatology</i> , 2010 , 52, 886-93	11.2	692
210	Profile of pre-S deletions in the natural history of chronic hepatitis B infection. <i>Journal of Medical Virology</i> , 2010 , 82, 1843-9	19.7	12

209	Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2009 , 15, 3288-97	5.6	29
208	The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1940-6; quiz 1947	0.7	61
207	Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1779-85	5.9	18
206	The saga of entecavir. <i>Hepatology International</i> , 2009 , 3, 421-4	8.8	2
205	Hepatitis B and C virus-related carcinogenesis. <i>Clinical Microbiology and Infection</i> , 2009 , 15, 964-70	9.5	96
204	Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. <i>Journal of Hepatology</i> , 2009 , 50, 80-8	13.4	411
203	Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. <i>Journal of Hepatology</i> , 2009 , 50, 289-95	13.4	90
202	Prevention and management of drug resistance for antihepatitis B treatment. <i>Lancet Infectious Diseases, The</i> , 2009 , 9, 256-64	25.5	34
201	Mutational analysis for Wilson's disease. <i>Lancet, The</i> , 2009 , 374, 662	4.0	9
200	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , 2009 , 14, 679-685	1.6	8
199	Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. <i>Liver International</i> , 2008 , 28, 1408-16	7.9	68
198	New paradigms for the treatment of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 1182-92	4	19
197	HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. <i>Gastroenterology</i> , 2008 , 135, 1192-9	13.3	305
196	Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. <i>Vaccine</i> , 2008 , 26, 6587-91	4.1	62
195	LB80380: a promising new drug for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1581-8	5.9	19
194	Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1663-73	0.7	147
193	Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1421-6	0.7	43
192	Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. <i>Journal of Infectious Diseases</i> , 2008 , 198, 808-12	7	74

191	Chronic hepatitis B--new goals, new treatment. <i>New England Journal of Medicine</i> , 2008 , 359, 2488-91	59.2	92
190	Telbivudine for chronic hepatitis B: the GLOBE trial. <i>Future Virology</i> , 2008 , 3, 317-323	2.4	2
189	What is the best end point for hepatitis B treatment?. <i>Annals of Internal Medicine</i> , 2008 , 148, 560; author reply 560-1	8	1
188	Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: identification of 17 novel mutations and its genetic heterogeneity. <i>Journal of Human Genetics</i> , 2008 , 53, 55-63	4.3	58
187	Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. <i>Gut</i> , 2008 , 57, 98-102	19.2	134
186	Treatment of Chronic Hepatitis C with Different Genotypes 2008 , 130-147		2
185	Natural history of hepatitis-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008 , 14, 1652-6	5.6	175
184	Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. <i>Hepatology</i> , 2007 , 46, 1695-703	11.2	103
183	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. <i>Liver Transplantation</i> , 2007 , 13, 349-60	4.5	204
182	Intestinal tuberculosis mimicking fistulizing Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 137-9	4	12
181	Prediction of treatment outcomes for lamivudine. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 964-5	4	3
180	Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 269-75	3.4	30
179	Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 377-82	6.1	31
178	Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. <i>Journal of Infection</i> , 2007 , 54, 497-503	18.9	10
177	Hepatitis B virus genotypes: natural history and implications for treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007 , 1, 321-8	4.2	11
176	Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 3935-41	9.7	25
175	Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 3942-7	9.7	124
174	The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. <i>Annals of Internal Medicine</i> , 2007 , 147, 58-61	8	135

173	Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. <i>Annals of Internal Medicine</i> , 2007 , 147, 745-54	8	148
172	Etiologies of chronic liver diseases in Hong Kong. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 659-64	2.2	19
171	Telbivudine versus lamivudine in patients with chronic hepatitis B. <i>New England Journal of Medicine</i> , 2007 , 357, 2576-88	59.2	641
170	Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. <i>Antiviral Therapy</i> , 2007 , 12, 41-6	1.6	15
169	Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. <i>Antiviral Therapy</i> , 2007 , 12, 1295-303	1.6	75
168	Adefovir Dipivoxil Monotherapy and Combination Therapy with Lamivudine for the Treatment of Chronic Hepatitis B in an Asian Population. <i>Antiviral Therapy</i> , 2007 , 12, 41-46	1.6	28
167	Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease. <i>Antiviral Therapy</i> , 2007 , 12, 1295-1304	1.6	175
166	Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies. <i>Current Hepatitis Reports</i> , 2006 , 5, 23-33		23
165	Recommendations and potential future options in the treatment of hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 2225-31	4	
164	Hepatitis B virus with primary resistance to adefovir. <i>New England Journal of Medicine</i> , 2006 , 355, 322-3; author reply 323	59.2	38
163	T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. <i>Clinical Infectious Diseases</i> , 2006 , 42, 1-7	11.6	70
162	Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. <i>Intervirology</i> , 2006 , 49, 96-8	2.5	31
161	Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. <i>New England Journal of Medicine</i> , 2006 , 354, 1011-20	59.2	948
160	Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 874-9	5.9	37
159	Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. <i>Gastroenterology</i> , 2006 , 130, 703-14	13.3	96
158	Entecavir. <i>Drugs</i> , 2006 , 66, 1623-1624	12.1	
157	Overcoming the problem of chronic hepatitis B. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006 , 3, 197-202		2
156	Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006 , 45, 553-9	13.4	73

155	Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006 , 45, 646-53	13.4	116
154	Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 573-83	6.1	60
153	Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1179-86	6.1	84
152	A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. <i>Hepatology Research</i> , 2006 , 35, 127-34	5.1	13
151	One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. <i>Antiviral Therapy</i> , 2006 , 11, 909-16	1.6	32
150	A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2006 , 11, 977-83	1.6	14
149	Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. <i>Antiviral Therapy</i> , 2006 , 11, 779-86	1.6	8
148	Significance of Viral Load, Core Promoter/Precore Mutations and Specific Sequences of Polymerase Gene in Hbv-Infected Patients on 3-Year Lamivudine Treatment. <i>Antiviral Therapy</i> , 2006 , 11, 779-786	1.6	17
147	One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels. <i>Antiviral Therapy</i> , 2006 , 11, 909-916	1.6	66
146	A Randomized Placebo-Controlled, Dose-Finding Study of Oral Lb80380 in Hbeag-Positive Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006 , 11, 977-984	1.6	29
145	A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Gastroenterology</i> , 2005 , 129, 528-36	13.3	325
144	Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1099-103	0.7	35
143	A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2005 , 129, 528-536	13.3	267
142	Telbivudine: an upcoming agent for chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2005 , 3, 489-94	5.5	7
141	Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 301-7	6.1	8
140	The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2005 , 12, 373-9	3.4	61
139	Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. <i>Journal of Viral Hepatitis</i> , 2005 , 12, 513-8	3.4	20
138	Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 21, 841-9	6.1	24

137	Mannose-binding lectin in chronic hepatitis B virus infection. <i>Hepatology</i> , 2005 , 42, 1037-45	11.2	79
136	Comparison of the COBAS TaqMan HBV test with the COBAS Amplicor monitor test for measurement of hepatitis B virus DNA in serum. <i>Journal of Medical Virology</i> , 2005 , 77, 486-90	19.7	10
135	Serological markers of liver cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2005 , 19, 91-9	2.5	95
134	Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. <i>Hepatology Research</i> , 2005 , 33, 216-24	5.1	51
133	Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. <i>Gut</i> , 2005 , 54, 1610-4	19.2	276
132	Determinants for the occurrence of acute exacerbation of hepatitis B virus infection in Chinese patients after HBeAg seroclearance. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 1594-9	9.7	5
131	The role of cholecystectomy in reducing recurrent gallstone pancreatitis. <i>Endoscopy</i> , 2004 , 36, 206-11	3.4	11
130	Specific considerations in the design of hepatitis B virus clinical studies in the far East. <i>Methods in Molecular Medicine</i> , 2004 , 96, 457-64		2
129	Detection of intrahepatic hepatitis B virus DNA and correlation with hepatic necroinflammation and fibrosis. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3920-4	9.7	18
128	Real-time PCR assay using molecular beacon for quantitation of hepatitis B virus DNA. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3438-40	9.7	33
127	Clinical evaluation of the digene hybrid capture II test and the COBAS AMPLICOR monitor test for determination of hepatitis B virus DNA levels. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3513-7	9.7	10
126	Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3932-6	9.7	12
125	Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 5036-40	9.7	31
124	Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. <i>Journal of Virology</i> , 2004 , 78, 13591-9	6.6	119
123	Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. <i>American Journal of Gastroenterology</i> , 2004 , 99, 2032-7	0.7	47
122	HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 4882-4	9.7	19
121	Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. <i>Carcinogenesis</i> , 2004 , 25, 1593-8	4.6	85
120	Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004 , 19, 1276-82	4	195

119	Outpatients undergoing therapeutic endoscopic retrograde cholangiopancreatography: six-hour versus overnight observation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004 , 19, 1163-8	4	12
118	PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. <i>Oncogene</i> , 2004 , 23, 4182-6	9.2	94
117	Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 401-6	6.1	6
116	SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. <i>Hepatology</i> , 2004 , 39, 302-10	11.2	275
115	HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. <i>Hepatology</i> , 2004 , 39, 1694-701	11.2	198
114	Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. <i>Hepatology</i> , 2004 , 40, 727-37	11.2	111
113	A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 2004 , 40, 719-26	11.2	86
112	Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. <i>Liver Transplantation</i> , 2004 , 10, 557-63	4.5	26
111	Adefovir dipivoxil in chronic hepatitis B infection. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2361-7	4	19
110	18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 941-5	6.9	78
109	Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis E antigen seroconversion. <i>Journal of Hepatology</i> , 2004 , 40, 1008-17	13.4	25
108	Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. <i>Journal of Hepatology</i> , 2004 , 41, 119-25	13.4	60
107	Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi). <i>Journal of Hepatology</i> , 2004 , 41, 686-7	13.4	14
106	New Antiviral Treatment for Chronic Hepatitis B 2004 , 47-56		
105	Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. <i>Clinical Infectious Diseases</i> , 2003 , 37, 593-7	11.6	34
104	Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1181-5	0.7	36
103	Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. <i>Transplantation</i> , 2003 , 76, 1174-9	1.8	54
102	Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. <i>Transplantation</i> , 2003 , 75, S41-4	1.8	29

101	Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. <i>Intervirolgy</i> , 2003 , 46, 373-6	2.5	24
100	Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. <i>Hepatology</i> , 2003 , 37, 36-43	11.2	59
99	Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. <i>Hepatology</i> , 2003 , 37, 562-7	11.2	126
98	A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. <i>Cancer</i> , 2003 , 97, 2776-82	6.4	11
97	Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. <i>Hepatology</i> , 2003 , 38, 1419-27	11.2	85
96	Cholangiocarcinoma in liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003 , 18, 337-41	4	11
95	Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 289-96	6.1	60
94	Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B results of a comparative study in 96 Chinese patients. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1181-1185	0.7	3
93	Long-term safety of lamivudine treatment in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2003 , 125, 1714-22	13.3	639
92	Does the addition of endoscopic sphincterotomy to stent insertion improve drainage of the bile duct in acute suppurative cholangitis?. <i>Gastrointestinal Endoscopy</i> , 2003 , 58, 500-4	5.2	59
91	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003 , 38, 257-65	13.4	338
90	Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. <i>Journal of Hepatology</i> , 2003 , 39, 850-5	13.4	49
89	Viral hepatitis B. <i>Lancet, The</i> , 2003 , 362, 2089-94	40	638
88	Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. <i>Annals of Oncology</i> , 2003 , 14, 1463-7	10.3	41
87	Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. <i>Clinical Infectious Diseases</i> , 2003 , 36, 687-96	11.6	534
86	Prognostic factors in severe exacerbation of chronic hepatitis B. <i>Clinical Infectious Diseases</i> , 2003 , 36, 979-84	11.6	42
85	A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. <i>Gut</i> , 2003 , 52, 416-9	19.2	97
84	Current and future antiviral agents for chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 481-5	5.1	7

83	Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. <i>Journal of Infectious Diseases</i> , 2003 , 187, 1071-4	7	56
82	Clinical experience and follow-up with lamivudine in the Asian population 2003 , 383-390		
81	Reversal of protein-losing enteropathy by liver transplantation. <i>Journal of Clinical Gastroenterology</i> , 2003 , 36, 86-7	3	8
80	Hepatitis B Virus Genotypes B and C Do Not Affect the Antiviral Response to Lamivudine. <i>Antiviral Therapy</i> , 2003 , 8, 531-534	1.6	49
79	Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy. <i>Journal of Medical Virology</i> , 2002 , 67, 334-8	19.7	16
78	A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. <i>Cancer</i> , 2002 , 94, 1747-52	6.4	188
77	Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding?. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 929-36	6.1	54
76	Memoir on hepatitis and liver disease history in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17 Suppl, S510	4	
75	Prevalence and significance of hepatitis GB virus-c/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 432-7	4	1
74	Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. <i>Hepatology</i> , 2002 , 36, 186-94	11.2	226
73	A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. <i>Hepatology</i> , 2002 , 36, 687-91	11.2	130
72	Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. <i>New England Journal of Medicine</i> , 2002 , 346, 2033-8	59.2	480
71	A randomised controlled trial of endoscopic sphincterotomy in acute cholangitis without common bile duct stones. <i>Gut</i> , 2002 , 51, 245-7	19.2	31
70	Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. <i>Journal of Infectious Diseases</i> , 2002 , 186, 1335-8	7	73
69	Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2002 , 35, 272-5	3	2
68	Mirtazapine-induced hepatotoxicity. <i>Journal of Clinical Gastroenterology</i> , 2002 , 35, 270-1	3	40
67	Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. <i>Gastroenterology</i> , 2002 , 123, 1831-8	13.3	249
66	Role of cholecystectomy in preventing recurrent cholangitis. <i>Gastrointestinal Endoscopy</i> , 2002 , 56, 55-60	5.2	8

65	Acute hepatitis as a presentation of acute appendicitis in an immunocompromised patient. <i>Journal of Clinical Gastroenterology</i> , 2002 , 35, 203-4	3	
64	Acute cholangitis—predictive factors for emergency ERCP. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 1633-7	6.1	45
63	Acute pancreatitis complicating acute exacerbation of chronic hepatitis B infection carries a poor prognosis. <i>Journal of Viral Hepatitis</i> , 2001 , 8, 459-64	3.4	19
62	Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. <i>Cancer</i> , 2001 , 91, 106-12	6.4	112
61	Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. <i>Hepatology</i> , 2001 , 33, 1527-32	11.2	486
60	Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. <i>Hepatology</i> , 2001 , 34, 139-45	11.2	177
59	Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. <i>Hepatology</i> , 2001 , 34, 785-91	11.2	303
58	Low molecular weight heparin-induced liver toxicity. <i>Journal of Clinical Pharmacology</i> , 2001 , 41, 691-4	2.9	25
57	Treatment of chronic hepatitis B. <i>Lancet Infectious Diseases</i> , 2001 , 1, 232-41	25.5	76
56	L-dT: An ongoing phase I/IIa dose-escalation trial in patients with chronic HBV infection (NV-02B-001). <i>Gastroenterology</i> , 2001 , 120, A572	13.3	2
55	Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. <i>Annals of Surgery</i> , 2001 , 233, 276-81	7.8	110
54	Profound suppression of hepatitis B virus replication with lamivudine. <i>Journal of Medical Virology</i> , 2000 , 61, 367-73	19.7	39
53	Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. <i>Hepatology</i> , 2000 , 31, 201-6	11.2	198
52	Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. <i>Hepatology</i> , 2000 , 31, 330-5	11.2	366
51	Natural history of chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15 Suppl, E20-4	4	51
50	Antiviral therapy for hepatitis B and C in Asians. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999 , 14 Suppl, S19-21	4	13
49	Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. <i>Liver International</i> , 1999 , 19, 444-51	7.9	23
48	Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. <i>Hepatology</i> , 1999 , 29, 924-7	11.2	57

47	Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. <i>Hepatology</i> , 1999 , 29, 1248-51	11.2	69
46	Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians. <i>Transplantation Proceedings</i> , 1999 , 31, 535-6	1.1	11
45	Nucleic acid-based cross-linking assay for detection and quantification of hepatitis B virus DNA. <i>Journal of Clinical Microbiology</i> , 1999 , 37, 161-4	9.7	27
44	Applicability of living donor liver transplantation to high-urgency patients. <i>Transplantation</i> , 1999 , 67, 73-7	1.8	58
43	A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. <i>New England Journal of Medicine</i> , 1998 , 339, 61-8	59.2	1589
42	Adult-to-adult living donor liver transplantation using extended right lobe grafts. <i>Annals of Surgery</i> , 1997 , 226, 261-9; discussion 269-70	7.8	446
41	Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up. <i>Journal of Vascular and Interventional Radiology</i> , 1996 , 7, 419-25	2.4	38
40	Hepatic expression of hepatitis B virus genome in chronic hepatitis B virus infection. <i>American Journal of Clinical Pathology</i> , 1996 , 105, 87-95	1.9	23
39	Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. <i>Transplantation</i> , 1996 , 62, 696-8	1.8	129
38	Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. <i>Hepatology</i> , 1995 , 22, 25-29	11.2	2
37	Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. <i>Hepatology</i> , 1995 , 22, 25-29	11.2	46
36	Clinicopathologic features of hepatitis C virus infection in renal allograft recipients. <i>Transplantation</i> , 1994 , 58, 996-1000	1.8	22
35	The hepatitis C virus genome: a guide to its conserved sequences and candidate epitopes. <i>Virus Research</i> , 1993 , 30, 27-41	6.4	20
34	Relationship between intrahepatic expression of hepatitis B viral antigens and histology in Chinese patients with chronic hepatitis B virus infection. <i>American Journal of Clinical Pathology</i> , 1993 , 100, 648-53	1.9	11
33	Recombinant interferon- α in inoperable hepatocellular carcinoma: A randomized controlled trial. <i>Hepatology</i> , 1993 , 17, 389-394	11.2	191
32	Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. <i>Hepatology</i> , 1993 , 18, 763-7	11.2	48
31	Recombinant interferon- α in inoperable hepatocellular carcinoma: A randomized controlled trial 1993 , 17, 389		10
30	A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. <i>Gastroenterology</i> , 1992 , 102, 2091-7	13.3	218

29	Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong. <i>Journal of Hepatology</i> , 1992 , 14, 332-4	13.4	5
28	Significance of isolated anti-HBc seropositivity by ELISA: implications and the role of radioimmunoassay. <i>Journal of Medical Virology</i> , 1992 , 36, 180-3	19.7	40
27	Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus-related chronic liver diseases. <i>Hepatology</i> , 1991 , 13, 834-7	11.2	15
26	Overestimation of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera. <i>Hepatology</i> , 1991 , 14, 756-62	11.2	43
25	Current seroepidemiology of hepatitis A in Hong Kong. <i>Journal of Medical Virology</i> , 1991 , 34, 191-3	19.7	32
24	Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 1990 , 12, 1266-70	11.2	72
23	Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. <i>Journal of Hepatology</i> , 1990 , 10, 29-34	13.4	220
22	Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcer. <i>Digestive Diseases and Sciences</i> , 1989 , 34, 1494-500	4	12
21	alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. <i>Hepatology</i> , 1989 , 9, 110-5	11.2	164
20	Synergism of chronic alcoholism and hepatitis B infection in liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1989 , 4, 11-6	4	14
19	Factors determining the development of hepatocellular carcinoma in hepatitis B surface antigen carriers. A comparison between families with clusters and solitary cases. <i>Cancer</i> , 1988 , 61, 1287-91	6.4	25
18	Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. <i>Cancer</i> , 1988 , 62, 479-83	6.4	326
17	Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. <i>Hepatology</i> , 1988 , 8, 766-70	11.2	121
16	A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. <i>Hepatology</i> , 1988 , 8, 1130-3	11.2	157
15	Necrotizing enterocolitis in neonates with symptomatic congenital heart disease. <i>Journal of Pediatrics</i> , 1988 , 113, 1044-6	3.6	58
14	Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. <i>Lancet, The</i> , 1988 , 2, 298-302	40	144
13	Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. <i>Gastroenterology</i> , 1987 , 92, 1839-43	13.3	285
12	Hepatitis B virus infection in Chinese families in Hong Kong. <i>American Journal of Epidemiology</i> , 1987 , 126, 492-9	3.8	118

11	An oligonucleotide probe for the detection of hepatitis B virus DNA in serum. <i>Journal of Virological Methods</i> , 1987 , 15, 139-49	2.6	26
10	Pathogenetic role of <i>Campylobacter pyloridis</i> in gastric ulcer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987 , 2, 309-316	4	13
9	Absence of transmission of hepatitis B by fiberoptic upper gastrointestinal endoscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987 , 2, 175-180	4	16
8	Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. <i>Lancet, The</i> , 1987 , 2, 877-80	4 ⁰	143
7	Hepatocellular carcinoma in Chinese males and females. Possible causes for the male predominance. <i>Cancer</i> , 1987 , 60, 1107-10	6.4	38
6	Persistence of <i>Campylobacter pyloridis</i> despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. <i>Digestive Diseases and Sciences</i> , 1987 , 32, 1255-60	4	47
5	Prostaglandin E1 (misoprostol) overcomes the adverse effect of chronic cigarette smoking on duodenal ulcer healing. <i>Digestive Diseases and Sciences</i> , 1986 , 31, 68S-74S	4	58
4	Interferon therapy of chronic hepatitis B virus infection in Chinese. <i>Journal of Hepatology</i> , 1986 , 3 Suppl 2, S209-15	13.4	21
3	Chronic antral gastritis in duodenal ulcer. Natural history and treatment with prostaglandin E1. <i>Gastroenterology</i> , 1986 , 91, 1095-101	13.3	33
2	Factors influencing healing of duodenal ulcer. Control of nocturnal secretion by H2 blockade and characteristics of patients who failed to heal. <i>Digestive Diseases and Sciences</i> , 1985 , 30, 45-51	4	36
1	Case report of symptomatic porphyria cutanea tarda associated with histiocytic lymphoma. <i>Cancer</i> , 1984 , 53, 573-6	6.4	11